Key facts, as of
As of October 8, 2026, Bristol-Myers Squibb (BMY) trades at $59.70, up 33.7% over the past year. Its 52-week range runs from $42.52 to $68.64; the price is 13.0% below that high. It is 26.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +64.6%, against +312.9% for the S&P 500 (SPY). It sits 0.4% above its 200-day average of $59.48, the usual sign of a long-term uptrend. Its 30-day volatility is 20.4% annualized, which we rate medium risk. It has a trailing P/E of 13.1 and a dividend yield of 4.22%.
Cite: Portfolio Terminal, "Bristol-Myers Squibb (BMY) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/bmy
Where it trades today
trading 66% of the way up its 52-week range
How the price has moved
How far it is from its record
Bristol-Myers Squibb (BMY) is 26.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +64.6%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- BMY trades at 13.1x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- BMY carries a beta of 0.18, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- BMY remains in a bearish short-term trend and sits 13.0% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- BMY is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for BMY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for BMY. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Bristol-Myers Squibb does
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of…
Employees
32,500
Industry
Drug Manufacturers - General
Headquarters
Princeton, United States
What analysts expect
BMY carries a buy consensus from 24 analysts, with an average price target of $66.17 versus $59.70 today (+10.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BMY generated $49.19B in trailing revenue (5.7% year over year), with a 18.9% net margin, and $8.11B of free cash flow, against $33.99B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $48.20B | $34.26B | $13.72B | $7.05B | $3.47 | $12.85B |
| 2024 | $48.30B | $34.33B | $5.89B | -$8.95B | -$4.41 | $13.94B |
| 2023 | $45.01B | $34.31B | $8.20B | $8.03B | $3.88 | $12.65B |
| 2022 | $46.16B | $36.02B | $9.10B | $6.33B | $2.97 | $11.95B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
BMY is in 9 of the 30 ETFs we track. It weighs most in SCHD: 3.17% of the fund, holding #14 of 100.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
BMY beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 7.2% below its 50-day average and 0.4% above its 200-day.
- RSI at 36 is neither stretched nor washed out.
- The nearest ceiling is $60.53 (+1.4%), the nearest floor $59.06 (-1.1%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is BMY a good investment in 2026?
Bristol-Myers Squibb trades at a P/E ratio of 13.1, with medium volatility (20.4% annualized). Recent trend shows weakness.
What is the risk level of BMY?
Based on 30-day volatility of 20.4%, BMY has MEDIUM risk. Beta of 0.18 indicates lower sensitivity to market movements than average.
Does BMY pay dividends?
Yes, Bristol-Myers Squibb has a dividend yield of 4.22%.
How far is BMY from its all-time high?
Bristol-Myers Squibb is 26.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +64.6%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold BMY?
9 of the 30 popular ETFs we track hold Bristol-Myers Squibb. The largest weights: SCHD (3.17%), XLV (2.03%), JEPI (0.64%), VYM (0.55%) and VTV (0.50%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is BMY?
0.21%, as of August 31, 2026: BMY is holding #85 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.06 in Bristol-Myers Squibb.
What is the analyst price target for BMY?
The average analyst price target for Bristol-Myers Squibb (BMY) is $66.17 based on 24 analyst estimates, about 10.8% above the current price of $59.70. The published range runs from $41.00 to $82.00.
How much revenue does BMY generate?
Bristol-Myers Squibb reported $49.19B in trailing twelve-month revenue. Revenue growth is running at 5.7% year over year. Net margin sits at 18.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BMY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.